Update on the diagnosis and treatment of prostate cancer

Current Opinion in Oncology

Volumn 10, Issue 3, 1998, Pages 244-252

  Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESTRAMUSTINE; FINASTERIDE; FLUTAMIDE; HORMONE; LEUPRORELIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER SCREENING; FAT INTAKE; HORMONAL THERAPY; HUMAN; IMPOTENCE; INCONTINENCE; MALE; METHODOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT;

EID: 0031804453     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199805000-00012     Document Type: Review

References (91)

1. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD: Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996, 30:138-144.
2. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, Nyren O: Body size and prostate cancer: a 20-year follow-up study among 135,006 Swedish construction workers. J Natl Cancer Inst 1997, 89:385-389.
3. Guess HA, Friedman GD, Sadler MC, Stanczyk FZ, Vogelman JH, Imperato-McGinley J, Lobo RA, Orentreich N: Five alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomarkers Prev 1997, 6:21-24.
4. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein •• MJ, Bova GS, Guo H, Bujnovsky P, et al.: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996, 274:1371-1374. The first demonstration of a putative "prostate cancer gene." This study identified a presumed susceptibility locus, although specific tumor suppressor genes or oncogenes have not yet been identified.
5. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF: Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset J Clin Endocrinol Metab 1996, 81:4400-4405.
6. Giovanucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, • Hennekens CH, Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997, 94:3320-3323. Identifies one of the genetic polymorphisms most strongly linked with outcome in prostate cancer. The exact causative mechanism remains to be worked out.
7. Ingles SA, Ross RK, Yu MC, Irvine RA, LaPera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997, 89:166-170.
8. Collins MM, Ransohoff DF, Barry MJ: Early detection of prostate cancer: serendipity strikes again. JAMA 1997, 278:1516-1519.
9. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG: Early detection of prostate cancer: part II. Estimating the risks, benefits, and costs. Ann Intern Med 1997, 126:468-479.
10. Collins MM, Barry MJ: Controversies in prostate cancer screening: analogies to the early lung cancer screening debate. JAMA 1996, 276:1976-1979.
11. Jacobsen SJ, Bergstralh EJ, Guess HA, Katusic SK, Klee GG, Oesterline JE, Lieber MM: Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med 1996, 156:2462-2468.
12. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV: Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens. A different view. J Urol 1997, 157:244-250.
13. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997, 157:2212-2218.
14. Schwartz KL, Severson RK, Gurney JG, Montie JE: Trends in the stage • specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. Cancer 1996, 78:1260-1266. This SEER program data suggest that PSA screening has resulted in a clear shift in characteristics of incident prostate cancer cases, most dramatically toward earlier stage tumors.
15. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schroeder FH: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997, 157:2191-2196.
16. Prestigiacomo AF, Stamey TA: Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 1997, 157:189-194.
17. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW: Analysis of percent-free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996, 48:55-61.
18. Morgan TO, McLeod DG, Leiter ES, Murphy GP, Moul JW: Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996, 48:76-80.
19. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997, 277:1452-1455.
20. Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, Stamey TA, Prestigiacomo AR, Brawer MK, Petteway JC, et al.: Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 1996, 48:45-50.
21. Pannek J, Subone EN, Jones KA, Marschke PL, Epstein JI, Chan DW, Carter HB, Luderer AA, Partin AW: The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology 1996, 48:51-54.
22. Cowen ME, Kattan MW, Miles BJ: A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer 1996, 78:1952-1957.
23. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul •• JW: Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996, 335:304-310. Points out that fundamental racial differences in prostate cancer biology (eg, what is considered a normal PSA level?) can account for some of the clinical observations suggesting that, in general, race is a risk factor for worse outcome.
24. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, Venable D, Sartor O: Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 1997, 89:134-138.
25. Presti JC Jr., Hovey R, Bhargava V, Carroll PR, Shinohara K: Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: Ethnic variations. J Urol 1997, 157:907-912.
26. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, •• Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997, 277:1445-1451. The so-called "Partin tables" continue to offer a unique risk assessment tool, although they are imperfect-with some validation data sets show considerable variability.
27. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT: Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997, 79:528-537.
28. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A: Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997, 49:23-30.
29. Sokoloff MH, Tso CL, Kaboo R, Nelson S, Ko J, Dorey F, Figlin RA, Pang S, deKernion J, Belldegrun A: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996, 156:1560-1566.
30. Byrne RL, Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC: The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997, 79:190-195.
31. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW: p53 Abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst 1997, 89:66-71
32. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996, 156:1511-1516.
33. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K: Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996, 74:910-916.
34. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M, Kubota Y: Telomerase activity in primary prostate cancer. J Urol 157:1161-1165.
35. Stattin P, Damber JE, Karlberg L, Bergh A: Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 157:219-222.
36. Coetzee LJ, Layfield LJ, Hars V, Paulson DF: Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage? J Urol 1997, 157:214-218.
37. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA: Family history •• of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997, 15:1478-1480. Genetic linkage studies have identified a prostate susceptibility locus. This study in turn provides the clinical evidence to suggest that there exists an unidentified familial factor that is also a marker for poor outcome after treatment of patients with localized prostate cancer.
38. Powell IJ, Heilbrun LK, Sakr W, Grignon D, Montie J, Novallo M, Smith D, Pontes JE: The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins. Urology 1997, 49:726-731.
39. Krongrad A, Lai H, Lai S: Survival after radical prostatectomy. JAMA 1997, 278:44-46.
40. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Belanger A, Candas B: Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997, 49:56-64.
41. Abbas F, Scardino PT: Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 1996, 23:587-604.
42. Witjes WP, Schulman CC, Debruyne FM: Preliminary results of a •• prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma: The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997, 49:65-69. One of the first randomized studies of neoadjuvant hormonal therapy suggesting that the observed improvement in positive margin rates did not translate to PSA progression-free survival.
43. Bazinet M, Zheng W, Begin LR, Aprikian AG, Karakiewicz PI, Elhilali MM: • Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 1997, 49:721-725. Explains why neoadjuvant hormones administered prior to prostatectomy do not affect PSA progression.
44. Eastham JA, Kattan MW, Rogers E, Goad JR, Ohon M, Boone TB, Scardino PT: Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996, 156:1707-1713.
45. Robinson JW, Dufour MS, Fung TS: Erectile functioning of men treated for prostate carcinoma. Cancer 1997, 79:538-5344.
46. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, •• Bernier J, Kuten A, Sternberg C, Gil T, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300. This is probably the single most important radiation oncology paper, because it sets the standard for concurrent hormones plus radiation. This study did not include patients with low-grade, T1, or T2 tumors, although in clinical practice its findings have been translated to this group of patients.
47. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, et al.: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997, 15:1013-1021.
48. Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A, Labrie F: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37:247-252.
49. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, • Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU: p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997, 89:158-165. This provocative trial, despite its retrospective nature and subset analysis, raises the possibility of a negative interaction between mutant p53 gene status amd neoadjuvant hormonal therapy.
50. Roach M III, Meehan S, Kroll S, Weil M, Ryu J, Small EJ, Margolis LW, • Presti J Jr., Carroll PC, Phillips TL: Radiotherapy for high grade clinically localized carcinoma of the prostate. J Urol 1996, 156:1719-1723 This important paper suggests a possible improvement in freedom from progression when high doses of radiation are used against Gleason score 8 to 10 diseases.
51. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, Coia • LR: Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997, 37:543-550. The benefits of high-dose conformal radiation appeared to be restricted to patients with a PSA level of 10 to 20 ng/mL.
52. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE: Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37:3-11.
53. Mantz CA, Song P, Farhangi E, Nautiyal J, Awan A, Ignacio L, Weichselbaum R, Vijaykumar S: Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37:551-557.
54. Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott • JA: Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multi-institutional outcomes study. J Clin Oncol 1997, 15:223-229. This relatively small series begins to identify features associated with side effects after external-beam irradiation, and suggests improved outcome with conformal radiotherapy.
55. Eastham JA, Kattan MW, Groshen S, Scardino PT, Rogers E, Carlton CE Jr., Lerner SP: Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol 1997, 15:3214-3222.
56. Beyer DC, Priestley JB Jr.: Biochemical disease-free survival following I-121 prostate implantation. Int J Radiat Oncol Biol Phys 1997, 37:559-563.
57. Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC: Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37:31-39.
58. Critz FA, Levinson K, Williams WH, Holladay D, Holladay C, Griffin V: Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology 1997, 49:668-672.
59. Lu-Yao GL, Yao SL: Population-based study of long-term survival in •• patients with clinically localised prostate cancer. Lancet 1997, 349:906-910. This very large population-based study allows a comparison of outcomes with surgery, irradiation, and observation, albeit with retrospective, nonrandomized data.
60. Kupelian PA, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E: External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biospy Gleason scores. Cancer J Sci Am 1997, 3:78-87.
61. D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A, Coleman CN: Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997, 37:1053-1058.
62. Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen •• profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997, 15:230-238. One of the very few papers outlining the natural history of serologic progression. Surprisingly, the 5-year metastasis rate was 47%. There is tremendous variability in this group of patients, although the natural history is often predicted by doubling time.
63. Schild SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Novicki DE, Ferrigini RG: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996, 156:1725-1729.
64. Medini E, Medini I, Reddy PK, Levitt SH: Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy: a long-term follow-up. Cancer 1996, 78:1254-1259.
65. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997, 49:71-78.
66. Eisenberger MA: A comparison of bilateral orchiectomy (ORCII) with or •• without flutamide in stage D2 prostate cancer (PC) [abstract]. Proc Am Soc Clin Oncol 1997, 16:2a. Although only in abstract form, this large, well-designed study failed to show a survival advantage to adding flutamide to orchiectomy, calling into question the utility of CAB.
67. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NV, Chen Y, Kolvenbag GJ: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression. Casodex Combination Study Group. Cancer 1996, 78:2164-2169.
68. The Medical Research Council Prostate Cancer Working Party •• Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997, 79:235-246. This sentinel paper provides evidence that delayed androgen deprivation in patients with advanced prostate cancer is inferior to immediate therapy.
69. Townsend MF, Sanders WH, Northway RO, Graham SD Jr.: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997 79:545-550.
70. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 1997, 157:439-443.
71. Oliver RT, Williams G, Paris AM, Blandy JP: Intermittent androgen deprivation after PSA: complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997, 49:79-82.
72. Higano CS, Ellis W, Russell K, Lange PH: Intermittent androgen suppression with leuprolide and flutatmide for prostate cancer: a pilot study. Urology 1996, 48:800-804.
73. Grossfeld GD, Small EJ, Carroll PR: Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998, 51:137-144.
74. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andnole GL: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996, 48:901-905.
75. Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz • AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE: Phase II trial of suramin, leuprolide and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997, 15:1470-1477. Although this study using therapy simultaneously directed at hormone-sensitive (CAB) and -insensitive (suramin) clones was encouraging, a randomized trial is required for validation.
76. Small EJ, Vogelzang NJ: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997, 15:382-388.
77. Huan SD, Gerndzen RG, Yau JC, Stewart DJ: Antiandrogen withdrawal syndrome with nilutamide. Urology 1997, 49:632-634.
78. Small EJ, Baron AD, Fippin L, Apopdaca D: Ketoconazole retains activity • in advanced prostate cancer patients with progression despite flutatmide withdrawal. J Urol 1997, 157:1204-1027. One of the first manuscripts to explore the use of second-line hormone therapy after antiandrogen withdrawal. An encouraging PSA response proportion with only modest toxicity is reported.
79. Small EJ, Baron AD, Bok R: Simultaneous antiandrogen withdrawal and treatment with ketoconazole in patients with advanced prostate cancer. Cancer 1997, 80:1755-1759.
80. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, • Kolvenbag G, Shapiro L, Schwartz M: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997, 15:2928-2938. Establishes the response rate with second-line bicalutamide therapy, and points out that its utility is dependent on prior hormonal maneuvers.
81. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ: High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998, 159:149-153.
82. Scher HI, Mazumdar M, Kelly WK: Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 1996, 88:1623-1634.
83. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C: Phase II trial of 96-hour paclitaxel plus oral estramustme phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997, 15:3156-3163.
84. Tu S-M, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ: Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol 1996, 2:191-197.
85. Schmid HP, Maibach R, Bernhard J, Hering F, Hanselmann S, Gusset H, Morant R, Pestalozzi D, Castiglione M: A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubline time: Swiss Group for Clinical Cancer Research, Berne, Switzerland. Cancer 1997, 79:1703-1709.
86. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR: A prospective study of suramin-induced peripheral neuropathy. Brain 1996, 119:2039-2052.
87. Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ: Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996, 78:2411-2420.
88. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: • T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996, 29:371-380. One of the first trials describing immune therapy for prostate cancer with a novel technology using dendritic cells.
89. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CED, Neal DE, Hamdy FC: BCL-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996, 74:1258-1262.
90. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ: Expression of BCL-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997, 157:569-574
91. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997, 3:1381-1388.